Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018

  • ID: 4340516
  • Drug Pipelines
  • Region: Global
  • 59 pages
  • DelveInsight
1 of 3
“Fabry Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018” offers comprehensive Insight on marketed and Phase III products for Fabry Disease. The marketed products information covers their product details, patents (US & EU)*, historical and forecasted sales till 2022. It further provides the marketed products’ API manufacturer details for United States, Europe, China, and India.* The report also covers the emerging Phase III pipeline assets for Infantile Spasm including their detailed product profiles. Additionally, the report also highlights the future competitive landscape for Fabry Disease therapeutics.

*Depending on information availability

Comprehensive coverage of the following for Fabry Disease:

Marketed Products for Fabry Disease

Descriptive marketed product profiles for Fabry Disease including (but not limited to) drug description, regulatory milestones, product development and R&D activities encompassing clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are the historical and forecasted global sales till 2022 for each product.

Global API Manufacturers of Marketed Products for Fabry Disease

Coverage of API manufacturers for Fabry Disease marketed products spanning across United States, Europe, China and India. The manufacturers’ details include manufacturers’ name along with their location

Emerging Phase III products for Fabry Disease

Descriptive Phae III product profiles for Infantile Spasm including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Also provided are their forecasted global sales till 2022.

Methodology

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
  • A comprehensive coverage of Fabry Disease marketed products including product description, regulatory milestones, clinical trials, deals and partnerships have been elaborated in this report
  • Patent information around Fabry Disease marketed products in United States (US) and Europe (EU) has been highlighted
  • API manufacturers details for Fabry Disease marketed therapeutics in United States, Europe, China and India
  • Comprehensive coverage of the emerging therapies (Phase III) for Fabry Disease including their product description, research and development activities, collaborations and licensing deals, drug mechanism and chemical information
  • The report contains historical and forecasted global sales till 2022 for each marketed product and forecasted sales till 2022 for emerging Phase III products for Fabry Disease
Reasons to Buy
  • Establish a comprehensive understanding of Fabry Disease marketed and emerging (Phase III) products
  • Access to API manufacturers details for Fabry Disease marketed drugs to devise API procurement strategy for generic development
  • Plan developmental timelines around marketed drug patents for the major markets- US and EU
  • Understand current and future growth of marketed Fabry Disease therapeutics through their historical and forecasted sales
  • Identify and analyze future sales trends of emerging Phase III Fabry Disease therapeutics through their forecasted sales
  • Identify the products attributes and use it for target finding, drug repurposing, and precision medicine
  • Identify and plan ahead for prospective emerging players and their products for Fabry Disease
READ MORE
Note: Product cover images may vary from those shown
2 of 3
Report Introduction
Overview
Causes
Symptoms
Pathophysiology
Epidemiology
Diagnosis
Treatment
Emerging Treatment Strategies
Comparative Analysis of Marketed and Emerging Products
Marketed Therapies
Galafold: Amicus Therapeutics
Product Description
Regulatory Milestones
Research and Development
Product Development Activities
Other Clinical Activities
Product Details
Europe
Global Sales
Global Active Pharmaceutical Ingredient Manufacturers for Migalastat
United States
China
Patent Details
(The list continues)
Emerging Therapy- Phase III
Future Competitive Landscape
Appendix

List of Tables:
Table 1: List of Marketed and Emerging Product
Table 2: Galafold Product Details, Europe
Table 3: Galafold, Annual Global Sales from 2017-2022 (in million USD)
Table 4: Active Pharmaceutical Ingredient Manufacturers for Migalastat Region wise
Table 5: API Manufacturers for Migalastat for the United States
Table 6: API Manufacturers for Migalastat for China
Table 7: Patent Details: Migalastat
Table 8: Replagal Product Details, Europe
Table 9: Replagal, Annual Global Sales from 2013-2022 (in million USD)
Table 10: API Manufacturer for Agalsidase alfa for China
Table 11: Patent Details: Replagal
Table 12: Fabrazyme Product Details, United States
Table 13: Fabrazyme Product Details, Europe
Table 14: Fabrazyme, Annual Global Sales from 2013-2022 (in million USD)
Table 15: API Manufacturers for Agalsidase beta for the United States
Table 16: Patent Details: Fabrazyme
Table 17: PRX-102, Annual Forecasted Global Sales from 2019-2022 (in million USD)
Table 18: Venglustat, Annual Forecasted Global Sales from 2019-2022 (in million USD)

List of Figures:
Figure 1: Genetics of Fabry Disease
Figure 2: Signs and Symptoms of Fabry Disease
Figure 3: Pathophysiology of X-Linked Fabry Disease
Figure 4: Current and Emerging Treatment Therapies for Fabry Disease
Figure 5: Comparative Analysis of Marketed and Emerging Product
Figure 6: Galafold, Annual Global Sales from 2017-2022 (in million USD)
Figure 7: Active Pharmaceutical Ingredient Manufacturers for Migalastat Region wise
Figure 8: Replagal, Annual Global Sales from 2013-2022 (in million USD)
Figure 9: Fabrazyme, Annual Global Sales from 2013-2022 (in million USD)
Figure 10: PRX-102, Annual Forecasted Global Sales from 2019-2022 (in million USD)
Figure 11:Venglustat, Annual Forecasted Global Sales from 2019-2022 (in million USD)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll